Christian Angermayer's three years

Lede

Four days after President Trump signed the 18 April 2026 executive order accelerating psychedelic treatments, Christian Angermayer sat down with CNBC and described 2025 as the year psychedelics had stepped onto the global stage. The interview was given the day a German-born, Monaco-resident family-office founder probably most wanted to give it. Apeiron Investment Group, the firm Angermayer founded in 2007 and which now manages more than two and a half billion dollars across offices in London, New York City, Abu Dhabi, and Berlin, has anchored the biotech-equity capital flow behind the psychedelic renaissance for the better part of the last decade. atai Life Sciences, the holding entity for Apeiron’s senior psychedelic biotech position, completed a strategic combination with Beckley Psytech in November 2025 to form AtaiBeckley, an integrated psychedelic-biotech entity with a multi-asset pipeline. The April 2026 executive order’s Commissioner’s National Priority Voucher mechanism, the leontia analysis of which sits alongside this article, runs directly through AtaiBeckley’s lead asset.

Angermayer’s CNBC framing of 2025 was correct in arithmetic and structurally correct in framing. The arc that ran through the August 2024 Lykos rejection, the 2025 Compass Pathways Phase 3 results, the AtaiBeckley merger, and the February 2026 second Compass Phase 3 readout has a single most identifiable UHNW protagonist. This article is about the architecture of his three-year position.

What Apeiron actually is

Apeiron Investment Group sits inside a small but distinctive category of post-2010 European single-family offices. The firm operates with no investor capital, only Angermayer’s personal capital. The 2.5 billion dollar AUM figure represents the family-office balance sheet, not third-party assets. The roughly fifty people Apeiron employs are spread across four offices: London (the operational seat), New York (the US-facing capital deployment seat), Abu Dhabi (the Gulf-and-Asia interface), and Berlin (the German-speaking-market base and Angermayer’s national base). The geographic shape is consistent with the European UHNW pattern. The Monaco residence for the founder personally follows the same pattern as many European family-office principals.

Apeiron declares seven investment verticals. Six are standard family-office categories: Life Sciences, FinTech and Crypto, Future Tech, Natural Resources and Clean Energy, Real Estate, Media and Entertainment. The seventh vertical is named Experiences, Hospitality and Happiness. No other comparable European or American single-family office in the leontia register declares Happiness as a discrete asset category at the vertical level.

The Experiences, Hospitality and Happiness vertical is editorially load-bearing. It reflects an Apeiron thesis that the psychedelic and wellness economy combines into a UHNW asset category in its own right, not merely a Life Sciences sub-vertical. The thesis is operational. atai Life Sciences sits inside Life Sciences. Wellness-retreat positions, hospitality holdings, and category-defining experiential investments sit inside the seventh vertical. The architecture is the closest single example in leontia coverage of a UHNW family office that has formally institutionalised a thesis on what the founder generation usually labels longevity, optimisation, or well-being into a discrete capital-allocation category.

The atai Life Sciences trajectory

Angermayer founded atai Life Sciences in 2018 as the consolidated psychedelic-biotech holding entity. The structure was unusual at founding. atai did not develop drugs directly. It held controlling or significant positions in a portfolio of psychedelic-biotech companies developing individual assets. The portfolio approach was the structural answer to the regulatory uncertainty of the 2018 to 2024 period. Single-asset failure would not extinguish the holding entity.

atai IPO’d on NASDAQ in June 2021, raising approximately 225 million dollars at a fully-diluted valuation north of two billion dollars. The IPO timing was the peak of the post-pandemic psychedelic-biotech sentiment cycle. The stock traded down meaningfully through 2022 and 2023 as the broader biotech sector contracted and the Lykos FDA setback became the structural shadow.

The November 2025 strategic combination with Beckley Psytech, a UK-incorporated specialist in 5-MeO-DMT formulation work led by Cosmo Feilding Mellen (son of the longtime UK psychedelic-research advocate Amanda Feilding), consolidated the post-2024 strongest single asset in the post-Lykos pipeline. Beckley Psytech’s BPL-003, an intranasal formulation of mebufotenin (5-MeO-DMT) for treatment-resistant depression, reported positive Phase 2b results in July 2025 across 193 patients at 38 sites in six countries. The FDA granted BPL-003 Breakthrough Therapy designation in October 2025. The merger completed in November 2025. The combined entity is named AtaiBeckley.

The financing that supported the merger was a 50 million dollar private placement co-led by Ferring Ventures, the Swiss family-controlled venture arm of Ferring Pharmaceuticals, and Apeiron Investment Group. Ally Bridge Group and ADAR1 participated. The financing closed inside the same quarter that Compass Pathways reported its first Phase 3 positive readout. The structural narrative of the post-Lykos period was set inside one quarter.

Why Angermayer specifically

The leontia register includes several UHNW principals with documented psychedelic-economy positions. Peter Thiel and Founders Fund were early Compass Pathways backers. Bob Parsons of GoDaddy was one of the largest single individual donors to MAPS through the Phase 3 trial period. Tim Ferriss has been a long-term advocate and funder both directly and through his media platform. The Steven and Alexandra Cohen Foundation and Rebekah Mercer have been documented MAPS supporters. Each of these positions is significant individually.

Angermayer’s position is structurally distinctive for three reasons.

The first is institutionalisation. Apeiron is a 2.5 billion dollar family office that formally codifies the psychedelic-and-wellness thesis at the vertical-strategy level. No other UHNW principal in the leontia register has formalised the category as a discrete vertical. Founders Fund’s psychedelic positions are tactical biotech-venture positions, not a declared thesis. Cohen Foundation and Mercer giving operate through MAPS philanthropy, not through equity-investment institutional architecture. The Apeiron seventh vertical is the only example of a senior UHNW principal who has organised a balance sheet around the category.

The second is concentration. atai Life Sciences and now AtaiBeckley are the single largest UHNW-anchored psychedelic-biotech holding entities. Compass Pathways is publicly listed with a more distributed shareholder base. Lykos Therapeutics emerged from MAPS and is non-equity philanthropic in origin. The post-Lykos consolidated equity-investable psychedelic biotech sector is, in operational terms, AtaiBeckley and Compass Pathways. Apeiron is the structural anchor of one and a major supporter of the other.

The third is voice. Angermayer is the single most-public UHNW principal in the category. His CNBC appearances, podcast interviews, written essays, and conference appearances run consistently through the period. His 2026 framing (“2025 will be remembered as the year psychedelics stepped onto the global stage”) is the kind of public protagonist statement that the broader category had been waiting for. No other UHNW principal in the leontia register has anchored the category at this level of public-facing presence.

For the leontia reader who tracks family-office allocation as a category, Angermayer is the cleanest single case study of UHNW capital allocation into the post-Lykos psychedelic-renaissance asset class.

What the three years showed

The 2024 to 2026 period was the cleanest single test of how UHNW family-office capital responds to a major regulatory setback in an emerging-category investment.

The Lykos FDA rejection in August 2024 was the structural shock. Apeiron did not exit. atai Life Sciences continued operating. Through 2025 the firm executed the Beckley Psytech transaction, supported the 50 million dollar PIPE, and absorbed the merger into AtaiBeckley by November 2025. Compass Pathways, the other senior listed psychedelic biotech, also continued operating and produced two positive Phase 3 readouts inside the same period.

The biotech-equity capital flow recovered. The philanthropic capital flow recovered more slowly: MAPS reduced staff by approximately 33 percent in late 2024 and the 33 percent staff cut is the operational baseline for the post-Lykos MAPS organisation as of mid-2026. The state-level commercial flow, addressed at length in the companion leontia piece on Oregon and Colorado, continued operating with its own operational pressures separate from the biotech regulatory arc.

The Apeiron-and-Angermayer post-Lykos behaviour is the cleanest data point for the broader UHNW investment thesis on the category. The principals who held biotech-equity exposure through the drawdown were vindicated by the 2025 and 2026 recovery. The principals who held philanthropic exposure are still recovering. The principals who were considering entry waited for the structural validation events (Compass Phase 3, AtaiBeckley merger, Trump executive order) and are now entering at the post-validation pricing rather than the pre-validation pricing.

What to watch

Three developments will define the Apeiron-and-AtaiBeckley trajectory over the next twelve to twenty-four months.

The first is the AtaiBeckley BPL-003 Phase 3 launch, expected in the second quarter of 2026. If the trial enrols with VA cooperation under the post-executive-order framework, BPL-003 could read out in 2027 to 2028. The Phase 3 result will determine whether AtaiBeckley has a near-term commercial pipeline beyond the Beckley Psytech merger thesis.

The second is the Compass Pathways NDA submission in the fourth quarter of 2026 and the subsequent approval timing. If COMP360 psilocybin reaches market in 2027, the listed psychedelic-biotech sector has a revenue-generating peer. Apeiron’s Compass Pathways exposure (through the early-stage investment alongside Founders Fund) will mark to market at that point. The category will have a real revenue line for the first time in modern history.

The third is whether Apeiron or another UHNW principal acquires Lykos Therapeutics or absorbs the MAPS-developed MDMA-PTSD asset. Lykos has continued to operate under the August 2024 Complete Response Letter, with the additional Phase 3 trial requirement still in front of it. A UHNW recapitalisation of Lykos by a structural acquirer (Apeiron, Founders Fund, a sovereign-wealth-fund-aligned biotech vehicle) would close the post-Lykos chapter and reframe MDMA-PTSD as the third leg of the psychedelic-biotech category alongside psilocybin and 5-MeO-DMT.

For the reader who tracks UHNW asset allocation as a category, the lesson of Angermayer’s three years is structural. The psychedelic renaissance was no longer a speculative bet by 2026. It was a category with a regulatory pathway, a state-level commercial layer, an international retreat circuit, and a named UHNW protagonist whose family office institutionalises the thesis at the vertical-strategy level. The three years closed with the renaissance back on the executive priority list. The next three years will determine whether AtaiBeckley becomes the senior anchor of the listed category and whether Apeiron’s Experiences Hospitality and Happiness vertical produces other consolidated holding entities in adjacent UHNW wellness categories.

Sources cited

1. AtaiBeckley IR, BioSpace, and Fierce Biotech on the June 2025 definitive agreement, July 2025 BPL-003 Phase 2b positive results, October 2025 FDA Breakthrough Therapy designation, November 2025 merger completion, and the 50 million dollar PIPE financing. See 2025-11 atai Beckley Psytech merger completed AtaiBeckley.
2. Forbes 2025 Billionaires List, Wikipedia, Apeiron Investment Group corporate disclosures, and the April 2026 CNBC interview with Christian Angermayer. See 2025-2026 Christian Angermayer Apeiron structural protagonist 1.2bn UHNW.
3. Compass Pathways IR and STAT on the February 2026 COMP006 second Phase 3 positive readout. See 2026-02 Compass Pathways COMP360 second Phase 3 positive readout.
4. Compass Pathways IR and HCPLive on the 2025 COMP005 first Phase 3 positive readout. See 2025 Compass Pathways COMP360 first Phase 3 positive readout precursor.
5. AJMC and Psychiatric Times on the August 2024 Lykos FDA Complete Response Letter and the September 2025 public release. See 2024-08 Lykos FDA rejection MDMA PTSD MAPS reorganization 33pc layoffs.
6. leontia synthesis on the UHNW funder network behind the renaissance, Founders Fund, Bob Parsons, Tim Ferriss, Rebekah Mercer, the Steven and Alexandra Cohen Foundation, Apeiron Investment Group. See UHNW funder network Founders Fund Parsons Ferriss Mercer Cohen.
7. White House Fact Sheet and NPR coverage of the 18 April 2026 executive order. See 2026-04-18 Trump executive order psychedelics 50m ibogaine veterans.

Sibling articles in the cluster

• Trump signed psychedelics into the executive priority list, the news-led companion piece on the regulatory pivot.
• The 95000 dollar psilocybin client, the operational state-level companion piece on Oregon and Colorado.